Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Novavax, Inc. - Common Stock (NQ:NVAX)

7.630 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Novavax, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
59 60 Next >
Novavax Stock Suffers Sharpest Drop In Months After $225M Debt Deal; Retail Still Leans Bullish
Bank of America’s downgrade to ‘Underperform’ with a $7 target deepened concerns over Sanofi’s limited commercialization of Nuvaxovid and higher hurdles for future partnerships. 
Via Stocktwits
Novavax Shares Are Trading Higher Thursday: What's Going On?
 
Via Benzinga
La-Z-Boy Posts Downbeat Q1 Results, Joins James Hardie Industries, Alcon And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
 
Via Benzinga
CDC Shooting Linked To Suspect's COVID-19 Vaccine Beliefs, Former Staff Blame RFK Jr. Hostility Toward Agency
CDC shooting tied to anti-vaccine beliefs sparks warnings from staff, as leaders clash over the future of mRNA vaccines and federal health policy. 
Via Benzinga
Novavax CFO Says Sanofi To Cover Majority Of Future Nuvaxovid Study Costs, Retail Urges Partnership Diversification
Via Stocktwits
Earnings Scheduled For August 6, 2025
 
Via Benzinga
Novavax Announces Positive Preclinical Data From Bird Flu Vaccine: Retail Wonders When Will The Stock Be Fairly Valued
Via Stocktwits
FDA May Not Renew Pfizer's Authorization For Covid Shots In Younger Children, Moderna Prepares To Boost Supply
Pfizer's COVID-19 vaccine for children under five may lose FDA authorization, leading to potential supply shortages. Modern on board to fill in gaps. 
Via Benzinga
Vinay Prasad's Comeback To FDA Sparks Debate Over Regulatory Direction
Vinay Prasad returns as FDA's CBER director after brief exit, raising questions on rare disease drug approvals and mRNA vaccine oversight. 
Via Benzinga
Former Surgeon General Slams RFK Jr. Over mRNA Cuts, Says US 'Conceding To China,' 2 Million Lives At Risk
Adams warns cutting funding for mRNA vaccine research will cost lives, derail medical progress, and give China an advantage. 
Via Benzinga
Novavax (NVAX) Profit Jumps on Milestone
Via The Motley Fool
Upcoming Earnings Calls This Week: August 4th - August 10th, 2025
This week, from August 4th to August 10th, 2025, marks a busy period in the second-quarter earnings season, with hundreds of companies across various sectors scheduled to report their financial... 
Via MarketMinute
Topics Artificial Intelligence Economy
Novavax Ups Outlook, Eyes Stronger Nuvaxovid Sales
Novavax beats Q2 expectations with $239 million in revenue, lifts 2025 guidance, and reports profit as costs decline and commercial rights shift to Sanofi. 
Via Benzinga
NOVAVAX INC (NASDAQ:NVAX) Surges on Q2 2025 Earnings Beat and FDA Approval for Nuvaxovid
Novavax (NVAX) stock surges 5.5% pre-market after Q2 2025 earnings crush estimates with $239M revenue and $0.62 EPS, fueled by Sanofi deal and FDA approval for Nuvaxovid. 
Via Chartmill
Topics Earnings
RFK Jr. Halts $500 Million In mRNA Vaccine Projects Backed By Pfizer, Moderna: 'We're Prioritizing Safer, Broader Strategies'
The Department of Health and Human Services will cancel 22 vaccine development projects totaling $500 million. 
Via Benzinga
Novavax Stock Dips As Moderna's Woes Weigh On Vaccine Sector
Shares of Novavax are trading lower Friday morning. The stock appears to be caught in a downdraft affecting COVID-19 vaccine makers after rival Moderna reported disappointing Q2 results. 
Via Benzinga
Novavax Shares Promising Results For Bird Flu Vaccine, Tested In Primates
Novavax reports strong immune responses from H5N1 avian flu vaccine candidate, showing promise in single and two-dose preclinical studies. 
Via Benzinga
2 Beaten-Down Stocks That Haven't Hit Rock Bottom Yet
Via The Motley Fool
Topics Cannabis
FDA Grants Complete Approval To Moderna's COVID-19 Vaccine For Children As Young As 6 Months
Moderna's Spikevax receives FDA approval for use in high-risk children; Pfizer, BioNTech appeal U.K. ruling in COVID-19 vaccine patent dispute. 
Via Benzinga
Topics Intellectual Property
Medical Groups Sue RFK Jr. For Assault On Science Over Unlawful COVID-19 Vaccine Rollbacks
Major health groups sue HHS and Robert F. Kennedy Jr. over COVID-19 vaccine policy changes for children and pregnant individuals. 
Via Benzinga
Cooling US Bird Flu Wave Removes Tailwind For Moderna, Novavax, CureVac, Traws Pharma
The CDC reportedly deactivated its bird flu emergency response last week, folding surveillance into its regular flu tracking and ending animal infection updates. 
Via Stocktwits
RFK Jr. Influence Evident As Vaccine Chief Overrules Scientists, Limits COVID-19 Vaccine Approval
FDA vaccine head Vinay Prasad restricted Moderna and Novavax COVID vaccines to high-risk groups, overriding staff advice amid concerns about rare side effects. 
Via Benzinga
CDC Vaccine Panel Overhauled by RFK Jr. Votes To Drop Mercury Preservative, Critics Sound Alarm
The panel also voted to recommend Merck’s RSV antibody drug Enflonsia for newborns whose mothers didn’t receive prenatal protection. 
Via Stocktwits
Moderna, Pfizer, Novavax Draw Bearish Buzz Ahead Of CDC Panel With Vaccine Skeptics
RFK Jr.'s newly appointed CDC panel, half of whom oppose vaccines, prepares to review key data on COVID, RSV, and flu shots. 
Via Stocktwits
Why Is Cidara Therapeutics Stock Trading Higher On Monday?
Cidara's CD388 met key goals in a Phase 2b flu trial, showing strong efficacy and safety data, with FDA talks planned for advancing to Phase 3. 
Via Benzinga
This Coinbase Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
 
Via Benzinga
BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal
BioNTech agreed to buy CureVac for $1.25 billion, expanding its mRNA cancer research and boosting its oncology pipeline. 
Via Benzinga
RFK Jr. Appoints Vaccine Critics To CDC Vaccine Panel After Firing Entire Advisory Committee: Report
Health Secretary Robert F. Kennedy Jr. named eight new members to the CDC's Advisory Committee on Immunization Practices. 
Via Benzinga
Novavax's Experimental COVID-19-Influenza Combo Shot Shows Immune Response Among Older Adults In Phase 3 Trial
Novavax's combo and standalone flu vaccines showed strong immune responses and good safety in a Phase 3 trial of adults 65 and older. 
Via Benzinga
Novavax’s Covid-Flu Combo, Standalone Flu Vaccines Demonstrate Robust Immune Response In Late-Stage Trial: Retail Says It’s ‘A Very Good Sign’
Both candidates were well tolerated, with nearly all adverse events identified as mild or moderate. 
Via Stocktwits
< Previous 1 2 3 4 5 6 7 8 9
...
59 60 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.